Eli Lilly And Co (LLY) Shares Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 4.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 506,744 shares of the company’s stock after buying an additional 22,169 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Eli Lilly And Co were worth $58,640,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in LLY. FDx Advisors Inc. grew its stake in shares of Eli Lilly And Co by 48.3% in the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock valued at $2,257,000 after buying an additional 6,356 shares in the last quarter. State of Alaska Department of Revenue grew its stake in shares of Eli Lilly And Co by 3.3% in the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock valued at $23,660,000 after buying an additional 6,474 shares in the last quarter. Waverton Investment Management Ltd grew its stake in shares of Eli Lilly And Co by 1.9% in the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock valued at $1,472,000 after buying an additional 238 shares in the last quarter. Sumitomo Life Insurance Co. grew its stake in shares of Eli Lilly And Co by 2.7% in the fourth quarter. Sumitomo Life Insurance Co. now owns 30,683 shares of the company’s stock valued at $3,551,000 after buying an additional 800 shares in the last quarter. Finally, Pennsylvania Trust Co grew its stake in shares of Eli Lilly And Co by 46.4% in the fourth quarter. Pennsylvania Trust Co now owns 85,021 shares of the company’s stock valued at $9,839,000 after buying an additional 26,947 shares in the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Eli Lilly And Co in a research note on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 target price for the company. Citigroup set a $124.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research note on Tuesday, February 26th. UBS Group decreased their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research note on Friday, February 8th. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Finally, Barclays reissued a “buy” rating and issued a $130.00 target price on shares of Eli Lilly And Co in a research note on Sunday, January 20th. Eleven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $113.06.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,000 shares of Eli Lilly And Co stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 833,190 shares of company stock valued at $102,388,102. Company insiders own 0.11% of the company’s stock.

LLY stock opened at $123.94 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. Eli Lilly And Co has a one year low of $74.51 and a one year high of $130.75. The firm has a market cap of $128.33 billion, a price-to-earnings ratio of 22.33, a P/E/G ratio of 2.49 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same period last year, the firm earned $1.14 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Eli Lilly And Co will post 5.62 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 8th. Shareholders of record on Friday, February 15th were given a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.08%. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date of this dividend was Thursday, February 14th. Eli Lilly And Co’s payout ratio is 46.49%.

COPYRIGHT VIOLATION NOTICE: “Eli Lilly And Co (LLY) Shares Bought by Nomura Asset Management Co. Ltd.” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.wkrb13.com/2019/03/17/eli-lilly-and-co-lly-shares-bought-by-nomura-asset-management-co-ltd.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.